View Financial HealthIcade 配当と自社株買い配当金 基準チェック /36Icade配当を支払う会社であり、現在の利回りは9.5%です。主要情報9.5%配当利回り0.003%バイバック利回り総株主利回り9.5%将来の配当利回り8.4%配当成長0.6%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向109%最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 04Icade, Annual General Meeting, Jun 10, 2026Icade, Annual General Meeting, Jun 10, 2026. Location: immeuble coeur deense, tour b espace comet, 24eme etage, 100 esplanade du general de gaulle, paris la defense cedex Franceお知らせ • Jan 14+ 2 more updatesIcade to Report Q3, 2026 Results on Oct 20, 2026Icade announced that they will report Q3, 2026 results at 6:00 PM, Central European Standard Time on Oct 20, 2026お知らせ • Oct 23Icade to Report Fiscal Year 2025 Results on Feb 17, 2026Icade announced that they will report fiscal year 2025 results After-Market on Feb 17, 2026お知らせ • Apr 05Icade, Annual General Meeting, May 13, 2025Icade, Annual General Meeting, May 13, 2025. Location: immeuble coeur defense, tour b espace comet, 24eme etage 100 esplanade du general de gaulle, paris Franceお知らせ • Jan 07+ 2 more updatesIcade to Report Q3, 2025 Results on Oct 22, 2025Icade announced that they will report Q3, 2025 results After-Market on Oct 22, 2025お知らせ • Oct 21Icade to Report Fiscal Year 2024 Results on Feb 18, 2025Icade announced that they will report fiscal year 2024 results After-Market on Feb 18, 2025お知らせ • Feb 19Icade, Annual General Meeting, Apr 19, 2024Icade, Annual General Meeting, Apr 19, 2024.お知らせ • Dec 14+ 1 more updateIcade to Report Q1, 2024 Results on Apr 22, 2024Icade announced that they will report Q1, 2024 results at 7:00 AM, Central European Standard Time on Apr 22, 2024お知らせ • Nov 23Icade to Report First Half, 2024 Results on Jul 22, 2024Icade announced that they will report first half, 2024 results on Jul 22, 2024お知らせ • Oct 23Icade to Report Fiscal Year 2023 Results on Feb 19, 2024Icade announced that they will report fiscal year 2023 results Pre-Market on Feb 19, 2024お知らせ • Sep 18Icade(ENXTPA:ICAD) dropped from FTSE All-World Index (USD)Icade(ENXTPA:ICAD) dropped from FTSE All-World Index (USD)お知らせ • Jul 07Primonial REIM and Société Générale Assurances completed the acquisition of 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders.Primonial REIM and Société Générale Assurances entered into an exclusivity agreement to acquire 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders for €1.4 billion on March 13, 2023. As of June 13, 2023, Primonial REIM and Société Générale Assurances entered into a definitive agreement to acquire 37.312% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders. Under the terms of transaction, €1.1 billion in Icade Santé shares to be sold to funds managed by Primonial and €100 million in Icade Santé shares to be sold to Société Générale Assurances, increasing its stake in Icade Santé. In addition, €200 million in shares would be repurchased by Icade Santé from Icade followed by their cancellation. As part of this stage, Icade Santé has secured €550 million in bank financing from Société Générale and BNP Paribas to finance the €200 million in capital reduction, as well as the repayment of the €50 million shareholder loan from Icade and the refinancing of the €300million bridge-to-bond facility entered into in March 2022. Upon completion of this first stage, Icade would lose control of Icade Santé, resulting in the deconsolidation of the subsidiary in the Icade Group’s consolidated financial statements. In addition, Primonial REIM would take over the management of the portfolio from the closing date. Lazard-Natixis acted asfinancial advisor to Icade (ENXTPA:ICAD). The Boards of Directors of Icade Santé and Icade were consulted in advance and, after examining the potential conflicts of interest, unanimously approved the transaction in accordance with the applicable provisions, in particular the rules governing regulated related party agreements. Transaction is subject to the signing of the final agreements once the process of informing and consulting Icade’s employee representative bodies has been completed and the regulatory conditions precedent have been met. These include confirmation by the French Financial Markets Authority (AMF) that the transaction will not give rise to a buyout offer with squeeze-out for Icade’s share capital, pursuant to Article 236-6 of the AMF’s general regulations. The first stage of the transaction, which should be completed before the end of July 2023. Icade’s remaining stake in Icade Santé is expected to be sold by the end of 2025, mainly to funds managed by Primonial REIM or to investors identified by Primonial REIM based on Icade Santé’s most recently published EPRA NTA on the sale date. The cash generated by this transaction will help Icade to fortify its balance sheet and seize potential growth opportunities. As of July 5, 2023. Icade Completes First Stage In Sale Of Icade Sante For €1.4 Billion. The Legal advisor, White & Case team in Paris which advised Icade Santé on the transaction was led by partners Thomas Le Vert and Jean Paszkudzki and included partners Raphaël Richard, Brice Engel and Alexandre Jaurett. The White & Case team in Paris which advised the minority shareholders Predica, Sogecap and Cardif was led by partner Nathalie Nègre-Eveillard. Gauthier Blanluet, Nicolas de Boynes and Alexis Madec of Sullivan & Cromwell LLP acted as accountant advising Icade and Icade Santé on the tax aspects of the transaction. SG Corporate & Investment Banking acted as Financial advisor for Primonial REIM. Primonial REIM and Société Générale Assurances completed the acquisition of 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders for €1.4 billion on July 5, 2023.お知らせ • Jun 06Vauban Infrastructure Partners and Icade (ENXTPA:ICAD) agreed to acquire A2A Coriance SAS.Vauban Infrastructure Partners and Icade (ENXTPA:ICAD) agreed to acquire A2A Coriance SAS on June 5, 2023. Transaction is subject to approval of regulatory and competing authority. Elodie Cavazza and Fabien Charmasson of Jeausserand-Audouard acted as legal advisor to Coriance .お知らせ • May 18Oteis France Sas agreed to acquire AMO and EXPERTISE SANTE activity from Icade (ENXTPA:ICAD).Oteis France Sas agreed to acquire AMO and EXPERTISE SANTE activity from Icade (ENXTPA:ICAD) on May 17, 2023. The transaction will cover the entire AMO and EXPERTISE SANTE scope, with the exception of a few contracts in the West Indies, Guyana, Reunion and a medical contract. This sale should be effective on June 30, 2023. Xavier Norlain and Aymeric Robine of Shearman & Sterling LLP acted as advisor to OTEIS Group.お知らせ • Jan 05An undisclosed buyer acquired Michigan Garden Project from Icade SA (ENXTPA:ICAD) for €108 million.An undisclosed buyer acquired Michigan Garden Project from Icade SA (ENXTPA:ICAD) for €108 million on November 28, 2022. The Michigan Garden project is scheduled for completion in Q4 2024 and will generate €108 millon in revenue. An undisclosed buyer completed the acquisition of Michigan Garden Project from Icade SA (ENXTPA:ICAD) on November 28, 2022.お知らせ • Dec 15+ 2 more updatesIcade SA to Report Q1, 2023 Results on Apr 24, 2023Icade SA announced that they will report Q1, 2023 results at 9:00 AM, Central European Standard Time on Apr 24, 2023お知らせ • Dec 14Icade SA to Report Fiscal Year 2022 Results on Feb 20, 2023Icade SA announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Feb 20, 2023決済の安定と成長配当データの取得安定した配当: CDMG.Fの配当金支払いは、過去10年間 変動性 が高かった。増加する配当: CDMG.Fの配当金支払額は過去10年間減少しています。配当利回り対市場Icade 配当利回り対市場CDMG.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CDMG.F)9.5%市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (REITs)5.3%アナリスト予想 (CDMG.F) (最長3年)8.4%注目すべき配当: CDMG.Fの配当金 ( 9.5% ) はUS市場の配当金支払者の下位 25% ( 1.41% ) よりも高くなっています。高配当: CDMG.Fの配当金 ( 9.5% ) はUS市場 ( 4.24% ) の配当支払者の中で上位 25% に入っています。株主への利益配当収益カバレッジ: CDMG.Fは高い 配当性向 ( 108.8% ) のため、配当金の支払いは利益によって十分にカバーされていません。株主配当金キャッシュフローカバレッジ: CDMG.Fの 現金配当性向 ( 48.5% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 17:13終値2026/05/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Icade 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21 アナリスト機関Celine HuynhBarclaysPaul MayBarclaysCeline HuynhBarclays18 その他のアナリストを表示
お知らせ • May 04Icade, Annual General Meeting, Jun 10, 2026Icade, Annual General Meeting, Jun 10, 2026. Location: immeuble coeur deense, tour b espace comet, 24eme etage, 100 esplanade du general de gaulle, paris la defense cedex France
お知らせ • Jan 14+ 2 more updatesIcade to Report Q3, 2026 Results on Oct 20, 2026Icade announced that they will report Q3, 2026 results at 6:00 PM, Central European Standard Time on Oct 20, 2026
お知らせ • Oct 23Icade to Report Fiscal Year 2025 Results on Feb 17, 2026Icade announced that they will report fiscal year 2025 results After-Market on Feb 17, 2026
お知らせ • Apr 05Icade, Annual General Meeting, May 13, 2025Icade, Annual General Meeting, May 13, 2025. Location: immeuble coeur defense, tour b espace comet, 24eme etage 100 esplanade du general de gaulle, paris France
お知らせ • Jan 07+ 2 more updatesIcade to Report Q3, 2025 Results on Oct 22, 2025Icade announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
お知らせ • Oct 21Icade to Report Fiscal Year 2024 Results on Feb 18, 2025Icade announced that they will report fiscal year 2024 results After-Market on Feb 18, 2025
お知らせ • Dec 14+ 1 more updateIcade to Report Q1, 2024 Results on Apr 22, 2024Icade announced that they will report Q1, 2024 results at 7:00 AM, Central European Standard Time on Apr 22, 2024
お知らせ • Nov 23Icade to Report First Half, 2024 Results on Jul 22, 2024Icade announced that they will report first half, 2024 results on Jul 22, 2024
お知らせ • Oct 23Icade to Report Fiscal Year 2023 Results on Feb 19, 2024Icade announced that they will report fiscal year 2023 results Pre-Market on Feb 19, 2024
お知らせ • Sep 18Icade(ENXTPA:ICAD) dropped from FTSE All-World Index (USD)Icade(ENXTPA:ICAD) dropped from FTSE All-World Index (USD)
お知らせ • Jul 07Primonial REIM and Société Générale Assurances completed the acquisition of 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders.Primonial REIM and Société Générale Assurances entered into an exclusivity agreement to acquire 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders for €1.4 billion on March 13, 2023. As of June 13, 2023, Primonial REIM and Société Générale Assurances entered into a definitive agreement to acquire 37.312% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders. Under the terms of transaction, €1.1 billion in Icade Santé shares to be sold to funds managed by Primonial and €100 million in Icade Santé shares to be sold to Société Générale Assurances, increasing its stake in Icade Santé. In addition, €200 million in shares would be repurchased by Icade Santé from Icade followed by their cancellation. As part of this stage, Icade Santé has secured €550 million in bank financing from Société Générale and BNP Paribas to finance the €200 million in capital reduction, as well as the repayment of the €50 million shareholder loan from Icade and the refinancing of the €300million bridge-to-bond facility entered into in March 2022. Upon completion of this first stage, Icade would lose control of Icade Santé, resulting in the deconsolidation of the subsidiary in the Icade Group’s consolidated financial statements. In addition, Primonial REIM would take over the management of the portfolio from the closing date. Lazard-Natixis acted asfinancial advisor to Icade (ENXTPA:ICAD). The Boards of Directors of Icade Santé and Icade were consulted in advance and, after examining the potential conflicts of interest, unanimously approved the transaction in accordance with the applicable provisions, in particular the rules governing regulated related party agreements. Transaction is subject to the signing of the final agreements once the process of informing and consulting Icade’s employee representative bodies has been completed and the regulatory conditions precedent have been met. These include confirmation by the French Financial Markets Authority (AMF) that the transaction will not give rise to a buyout offer with squeeze-out for Icade’s share capital, pursuant to Article 236-6 of the AMF’s general regulations. The first stage of the transaction, which should be completed before the end of July 2023. Icade’s remaining stake in Icade Santé is expected to be sold by the end of 2025, mainly to funds managed by Primonial REIM or to investors identified by Primonial REIM based on Icade Santé’s most recently published EPRA NTA on the sale date. The cash generated by this transaction will help Icade to fortify its balance sheet and seize potential growth opportunities. As of July 5, 2023. Icade Completes First Stage In Sale Of Icade Sante For €1.4 Billion. The Legal advisor, White & Case team in Paris which advised Icade Santé on the transaction was led by partners Thomas Le Vert and Jean Paszkudzki and included partners Raphaël Richard, Brice Engel and Alexandre Jaurett. The White & Case team in Paris which advised the minority shareholders Predica, Sogecap and Cardif was led by partner Nathalie Nègre-Eveillard. Gauthier Blanluet, Nicolas de Boynes and Alexis Madec of Sullivan & Cromwell LLP acted as accountant advising Icade and Icade Santé on the tax aspects of the transaction. SG Corporate & Investment Banking acted as Financial advisor for Primonial REIM. Primonial REIM and Société Générale Assurances completed the acquisition of 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders for €1.4 billion on July 5, 2023.
お知らせ • Jun 06Vauban Infrastructure Partners and Icade (ENXTPA:ICAD) agreed to acquire A2A Coriance SAS.Vauban Infrastructure Partners and Icade (ENXTPA:ICAD) agreed to acquire A2A Coriance SAS on June 5, 2023. Transaction is subject to approval of regulatory and competing authority. Elodie Cavazza and Fabien Charmasson of Jeausserand-Audouard acted as legal advisor to Coriance .
お知らせ • May 18Oteis France Sas agreed to acquire AMO and EXPERTISE SANTE activity from Icade (ENXTPA:ICAD).Oteis France Sas agreed to acquire AMO and EXPERTISE SANTE activity from Icade (ENXTPA:ICAD) on May 17, 2023. The transaction will cover the entire AMO and EXPERTISE SANTE scope, with the exception of a few contracts in the West Indies, Guyana, Reunion and a medical contract. This sale should be effective on June 30, 2023. Xavier Norlain and Aymeric Robine of Shearman & Sterling LLP acted as advisor to OTEIS Group.
お知らせ • Jan 05An undisclosed buyer acquired Michigan Garden Project from Icade SA (ENXTPA:ICAD) for €108 million.An undisclosed buyer acquired Michigan Garden Project from Icade SA (ENXTPA:ICAD) for €108 million on November 28, 2022. The Michigan Garden project is scheduled for completion in Q4 2024 and will generate €108 millon in revenue. An undisclosed buyer completed the acquisition of Michigan Garden Project from Icade SA (ENXTPA:ICAD) on November 28, 2022.
お知らせ • Dec 15+ 2 more updatesIcade SA to Report Q1, 2023 Results on Apr 24, 2023Icade SA announced that they will report Q1, 2023 results at 9:00 AM, Central European Standard Time on Apr 24, 2023
お知らせ • Dec 14Icade SA to Report Fiscal Year 2022 Results on Feb 20, 2023Icade SA announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Feb 20, 2023